Skip to main content

Table 1 Patient characteristics and prognosis

From: Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma

Patient Dose Age Sex P/R Curative MTD Tumor no. Tumor Background liver CP ALT PLT Prognosis
no.      treatment    histology F A     2 yrs 4.5 yrs
1 300 70 F P RFA 15 2 m-p 4 2 A 112 7.9 Rec Rec
2 600 72 F R RFA 20 2 w 4 2 A 40 7.9 Rec Rec λ
3 300 58 M P resection 25 1 m-p 2 1 A 16 19.2 nonRec nonRec
4 600 54 M P resection 25 1 m-p 3 2 A 57 16.4 nonRec Rec
5 600 60 F P RFA 23 1 m-p 4 2 B 23 6.4 nonRec nonRec
6 300 73 F P RFA 20 2 m-p 3 2 A 31 14.2 Rec Rec λ
7 300 69 F P RFA 11 3 w-m 4 1 A 38 11.5 Rec Rec λ
8 600 74 F P RFA 16 2 m-p 4 1 A 45 5.1 nonRec Rec
9 600 65 M R RFA 10 1 m-p 2 1 A 29 16.5 nonRec nonRec
10 600 59 M P resection 34 1 m-p 4 2 B 60 9.4 nonRec nonRec
11 300 70 F R RFA 15 1 w-m 4 2 B 98 7 nonRec nonRec
12 300 66 M P RFA 15 1 m-p 4 1 A 90 10.6 nonRec nonRec
  1. Dose (mg/day), ALT(U/L), PLT(×104/μL), MTD (mm).
  2. F; female, M; male, P; primary HCC, R; (first) recurrent HCC, MTD; maximum tumor diameter, w; well-differentiated, m; moderately differentiated, p; poorly differentiated, F; fibrosis stage, A; activity grade, CP; Child-Pugh classification, ALT; alanine aminotransferase, PLT; platelet.
  3. Rec; recurrence, nonRec; non-recurrence, λ; death.